- Research works
- 115 ▲ 122% vs 2013–17
- Citations
- 2.3k 20.2 per fractional work
- Top-10% rate
- 8.4% record average 16.5%
- Open access
- 58% world 28%
Not ranked overall: Immunocore (United Kingdom) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
What does Immunocore (United Kingdom) specialise in?
Where its research is concentrated relative to its size: Life Sciences takes 4.0× the share of its output that it takes of world research.
- Life SciencesDomain · 22.1 works4.0×
Location quotient, a volume reading rather than an impact one. It surfaces small, lopsided specialities.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 34.8×. Every wedge is a field page.
- Immunology and Microbiology 34.8×
- Biochemistry, Genetics and Molecular Biology 3.0×
- Pharmacology, Toxicology and Pharmaceutics 2.2×
- Medicine 2.2×
- Chemistry 0.3×
- Engineering 0.3×
- Materials Science 0.2×
- Economics, Econometrics and Finance 0.2×
- Neuroscience 0.2×
- Mathematics 0.1×
- Agricultural and Biological Sciences 0.1×
- Computer Science 0.0×
- Psychology 0.0×
Who are the top researchers at Immunocore (United Kingdom)?
Ranked on the composite score, Bent K. Jakobsen lead among researchers whose main affiliation is Immunocore (United Kingdom).
- 1 Bent K. Jakobsen United Kingdom · #1,350,998 worldwide 39 citations · 21 works
Which keywords describe research at Immunocore (United Kingdom)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Cancer Immunotherapy, Antigen Presentation, Immunotherapy, Dendritic Cells, Lymphoma, Tumor Regression, Immunity and CAR T Cells.
- Antiviral Therapy
- Peptide-MHC Binding
- Cancer Therapy
- Retinoblastoma
- Prognostic Factors
- PD-1 and PD-L1
- Glycosylation
- Antibody Engineering
- Tumor Microenvironment
- TGF-ß
- Natural Killer Cells
- Autoimmunity
- Tumor Antigen
- CAR T Cells
- Lymphoma
- Dendritic Cells
- Antigen Presentation
- Cancer Immunotherapy
- Immunotherapy
- Immunity
- Tumor Regression
- Chimeric Antigen Receptor
- Vaccine Adjuvants
- NK Cell Recognition
- Foxp3
- Monoclonal Antibodies
- Therapeutic Antibodies
- Fc Receptors
- Immune Checkpoint Blockade
- Genetic Mutations
- Immune Response
- Uveal Melanoma
- Epitope Prediction
- Inflammation
- Cancer
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 35 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 35 words, with their numbers
- Cancer Immunotherapy11▲ 170×3 topics
- Antigen Presentation7▲ 184×2 topics
- Immunotherapy6▲ 21×6 topics
- Dendritic Cells6▲ 151×2 topics
- Immunity6▲ 33×2 topics
- Lymphoma6▲ 84×2 topics
- Tumor Regression6▲ 124×2 topics
- CAR T Cells6▲ 183×1 topic
- Chimeric Antigen Receptor6▲ 183×1 topic
- Tumor Antigen5▲ 202×1 topic
- Vaccine Adjuvants5▲ 202×1 topic
- Autoimmunity4▲ 60×2 topics
- NK Cell Recognition4▲ 129×1 topic
- Natural Killer Cells4▲ 129×1 topic
- Foxp34▲ 251×1 topic
- TGF-ß4▲ 55×1 topic
- Monoclonal Antibodies3▲ 85×3 topics
- Tumor Microenvironment3▲ 17×4 topics
- Therapeutic Antibodies3▲ 96×2 topics
- Antibody Engineering3▲ 112×1 topic
- Fc Receptors3▲ 112×1 topic
- Glycosylation3▲ 55×2 topics
- Immune Checkpoint Blockade3▲ 56×1 topic
- PD-1 and PD-L13▲ 56×1 topic
- Genetic Mutations2▲ 14×4 topics
- Prognostic Factors2▲ 13×3 topics
- Immune Response2▲ 9.4×8 topics
- Retinoblastoma2▲ 366×1 topic
- Uveal Melanoma2▲ 366×1 topic
- Cancer Therapy2▲ 6.6×6 topics
- Epitope Prediction2▲ 144×1 topic
- Peptide-MHC Binding2▲ 144×1 topic
- Inflammation1▲ 1.65×7 topics
- Antiviral Therapy1▲ 25×3 topics
- Cancer1▲ 1.78×6 topics
Which research topics does Immunocore (United Kingdom) publish most on?
By volume in 2022–2025: CAR-T cell therapy research, Immunotherapy and Immune Responses, Immune Cell Function and Interaction and T-cell and B-cell Immunology.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 CAR-T cell therapy research Oncology 6 works
- 2 Immunotherapy and Immune Responses Immunology 5 works
- 3 Immune Cell Function and Interaction Immunology 4 works
- 4 T-cell and B-cell Immunology Immunology 4 works
- 5 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 3 works
- 6 Cancer Immunotherapy and Biomarkers Oncology 3 works
- 7 Ocular Oncology and Treatments Ophthalmology 2 works
- 8 vaccines and immunoinformatics approaches Molecular Biology 2 works
- 9 HIV Research and Treatment Virology 1 works
- 10 Atherosclerosis and Cardiovascular Diseases Immunology 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Immunocore (United Kingdom)'s research output changed?
Output in 2018–2022 was 122% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Abingdon
- United Kingdom Atomic Energy Authority
- Culham Science Centre
- Culham Centre for Fusion Energy
- Oxford Instruments (United Kingdom)
- Evotec (United Kingdom)
- Summit (United Kingdom)
- Tokamak Energy (United Kingdom)
- Adaptimmune (United Kingdom)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.